We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

133 hedge funds and large institutions have $485M invested in Cymabay Therapeutics in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 54 increasing their positions, 29 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

511% more call options, than puts

Call options by funds: $7.81M | Put options by funds: $1.28M

86% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 29

6% less funds holding

Funds holding: 142 → 133 (-9)

22% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 32

47% less capital invested

Capital invested by funds: $907M → $485M (-$422M)

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

Holders
133
Holders Change
-9
Holders Change %
-6.34%
% of All Funds
2.89%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.04%
New
25
Increased
54
Reduced
29
Closed
32
Calls
$7.81M
Puts
$1.28M
Net Calls
+$6.53M
Net Calls Change
+$5.77M

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$44.1M
2
ACA
Avoro Capital Advisors
New York
+$22.4M
3
Millennium Management
Millennium Management
New York
+$14.5M
4
Citigroup
Citigroup
New York
+$6.37M
5
BlackRock
BlackRock
New York
+$5.59M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$24.9M
2
GPP
Great Point Partners
Connecticut
-$13.3M
3
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$11.1M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$10.5M
5
CS
Credit Suisse
Switzerland
-$8.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$5.56M +$425K +37,542 +5%
Citigroup
27
Citigroup
New York
$4.17M +$6.37M +562,167 +2,815%
SSA
28
Schonfeld Strategic Advisors
New York
$4.1M +$3.04M +268,800 +89%
VVM
29
Versant Venture Management
California
$3.89M -$6.13M -540,943 -50%
Barclays
30
Barclays
United Kingdom
$2.87M +$3.83M +337,927 +536%
Charles Schwab
31
Charles Schwab
California
$2.81M +$319K +28,205 +8%
CS
32
Candriam SCA
Luxembourg
$2.69M -$6.79M -600,000 -61%
DCM
33
DAFNA Capital Management
California
$2.51M +$806K +71,185 +26%
N
34
Nuveen
North Carolina
$2.46M +$3.9M +344,046 New
B
35
Bailard
California
$2.21M +$1.06M +93,600 +44%
State of Wisconsin Investment Board
36
State of Wisconsin Investment Board
Wisconsin
$2.15M +$84.9K +7,500 +3%
UONDDL
37
University of Notre Dame du Lac
Indiana
$2.04M +$3.23M +285,301 New
Bank of New York Mellon
38
Bank of New York Mellon
New York
$1.94M +$149K +13,193 +5%
SIM
39
Spark Investment Management
New York
$1.73M +$661K +58,400 +32%
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$1.68M +$2.52M +222,471 +1,823%
Bank of America
41
Bank of America
North Carolina
$1.63M +$429K +37,862 +20%
EGM
42
Engineers Gate Manager
New York
$1.52M +$1.36M +120,487 +131%
Allianz Asset Management
43
Allianz Asset Management
Germany
$1.32M +$15.5K +1,370 +0.7%
Invesco
44
Invesco
Georgia
$1.11M +$1.76M +155,211 New
LOAMU
45
Lombard Odier Asset Management (USA)
New York
$1.04M -$396K -35,000 -19%
IG
46
ING Group
Netherlands
$1.04M +$646K +57,068 +65%
Goldman Sachs
47
Goldman Sachs
New York
$1.01M -$778K -68,743 -33%
A
48
Abingworth
United Kingdom
$937K – – –
Swiss National Bank
49
Swiss National Bank
Switzerland
$808K +$26K +2,300 +2%
AllianceBernstein
50
AllianceBernstein
Tennessee
$788K +$562K +49,600 +82%
1
2
3 4 5

CBAY Hedge Fund Activity: Q2 2019 in Review

133 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2019, worth a combined $485M — down 47% from $907M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of CBAY and 25 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 54 added.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $44.1M. The largest seller was OrbiMed, exiting entirely with an estimated $24.9M sold.

  • 133 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2019, down from 142 in Q1 2019.
  • Funds reported $485M of Cymabay Therapeutics stock for Q2 2019, down 47% quarter-over-quarter.
  • 25 funds opened new Cymabay Therapeutics positions in Q2 2019 and 32 closed out, a net change of -7 holders.
  • The largest Cymabay Therapeutics buyer in Q2 2019 was Point72 Asset Management, an estimated $44.1M added.
  • The largest Cymabay Therapeutics seller in Q2 2019 was OrbiMed, an estimated $24.9M sold.

Based on aggregated 13F filings for Q2 2019.